Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses

Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses

The invention relates to a compound R-(CR1R2)q-CO-N(R3)-C(R4R5)-CO-NH2 (I), wherein: R is a heterocyclyl radical; R1 and R2 independently represent H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 independently represent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MESSEGUER PEYPOCH ANGEL, RAMIREZ ORTIZ ANGEL, GONZALEZ RUIZ DOMINGO, SCHEPER SIGMUND JOHANNA, MASIP MASIP ISABEL, THOMSON OKATSU TIMOTHY, MORREALE DE LEON ANTONIO, SANCLIMENS PEREZ DE ROZAS GLOR, MOURE FERNANDEZ ALEJANDRA
Format: Patent
Sprache:chi ; eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to a compound R-(CR1R2)q-CO-N(R3)-C(R4R5)-CO-NH2 (I), wherein: R is a heterocyclyl radical; R1 and R2 independently represent H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 independently represent H or alkyl; q is a number between 0 and 1; and the salts, solvates, pro-drugs or stereoisomers thereof, which can inhibit UBC13-UEV interactions and be used in the production of pharmaceutical compositions intended for antitumour therapy or the treatment and/or prophylaxis of diseases associated with metabolic routes involving the UBC13 enzyme, metabolic routes involving transcriptional factor NF-kappaB or routes involving PCNA or RAD6.